Treatment efficacy of Ampicillin/Sulbactam in comparison to alternative beta-lactams for severe Acinetobacter baumannii infections

Infectious Diseases

Volumn 48, Issue 10, 2016, Pages 775-777

  Busey, Kirsten ^a   Ferreira, Jason ^a   Aldridge, Petra ^a   Johnson, Donald ^a   Guzman, Nilmarie ^a   Jankowski, Christopher A ^a  

^a UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; SULBACTAM;

ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BLOOD CULTURE; DISEASE SEVERITY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LETTER; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; DRUG EFFECTS; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84978519650     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.1080/23744235.2016.1193789     Document Type: Letter

References (9)

1. H.S.Lin, M.H.Lee, C.W.Cheng,. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47:370–378.
2. Centers for Disease Control and Prevention and National Healthcare Safety Network. Multidrug-Resistant organism and clostridium difficile infection (MDRO/CDI) module. January 2016; [cited 2016 Feb 28]. Available from: http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf
3. J.Fishbain, A.Y.Peleg Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51:79–84.
4. J.D.Chan, J.A.Graves, T.H.Dellit Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25:343–348.
5. G.C.Wood, S.D.Hanes, M.A.Croce,. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34:1425–1430.
6. D.Koulenti, J.Rello Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med. 2006;12:198–204.
7. S.T.Housman, M.Hagihara, D.P.Nicolau,. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013;68:2296–2304.
8. A.P.Betrosian, F.Frantzeskaki, A.Xanthaki,. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis. 2007;39:38–43.
9. A.P.Betrosian, F.Frantzeskaki, A.Xanthaki,. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56:432–436.